

EB/P/17

## PROPARGYLGLYCINE AND HYDROGEN SULFIDE EFFECTS ON PLASMA GALECTIN-3 IN STREPTOZOTOCIN-INDUCED DIABETIC RATS

Zaichko N.V., Palamarchuk I.V., Strutinska O.B.

Vinnitsa National Pirogov Memorial Medical University  
str.lena@i.ua, ikynchik00@gmail.com

**Background and aims:** The majority of diabetic patients are suffering from heart and kidney disease. Galectin-3 belongs to mediators of cardiac and renal fibrogenesis, while hydrogen sulfide (H<sub>2</sub>S), metabolite of sulfur-containing amino acids, is considered to have antifibrogenic effects. However, interaction between H<sub>2</sub>S system and galectin-3 associated with diabetes and its complications is undefined.

This study aimed to determine influence of H<sub>2</sub>S metabolism modulators (NaHS, propargylglycine) on plasma galectin-3 in rats with streptozotocin diabetes.

**Methods:** 32 healthy male rats (180-250 g) were divided into 4 groups. To induce diabetes, rats (group 2-4) were injected with streptozotocin (STZ, 40 mg/kg, i.p., 0.1 M citrate buffer (pH 4.5)). Rats (group 3-4) were administered NaHS (3 mg/kg, i.p.) or propargylglycine (50 mg/kg, i.p.) once per day starting from 3 to 28 days after streptozotocin injection. Rats of group 1 (control) were administered the equivalent volumes of 0.9% NaCl. Plasma galectin-3 was measured by ELISA. Rats' hearts and kidneys were sampled for determination of H<sub>2</sub>S by reaction with N,N-Dimethyl-p-phenylenediamine.

**Results:** Plasma galectin-3 in STZ-diabetic rats (group 2) was significantly higher than in controls ( $10.7 \pm 0.98$  ng/ml vs  $3.02 \pm 2.68$  ng/ml,  $p < 0.01$ ). While, H<sub>2</sub>S in myocardium and kidney of these rats (group 2) was decreased (in 1.37 - 1.48 times,  $p < 0.05$ ). Administration of H<sub>2</sub>S donor (NaHS) resulted in significant decrease of plasma galectin-3 (1.28 times,  $p < 0.05$ ), but propargylglycine administration (inhibitor of H<sub>2</sub>S-synthesising enzyme - cystathionine gamma-lyase) caused significant increase (in 1.56 times,  $p < 0.05$ ) of plasma galectin-3 (group 3-4). Increased plasma galectin-3 correlated with decreased H<sub>2</sub>S in myocardium and kidney of STZ-diabetic rats ( $r = 0.62; 0.59, p < 0.05$ ).

**Conclusions:** Plasma galectin-3 is increased in setting of STZ-diabetes in rats. Inhibition of H<sub>2</sub>S endogenous production could apparently enhance this effect, when NaHS administration led to reduction in plasma galectin-3. Thus, H<sub>2</sub>S system can be integrated in pathogenesis of diabetic complications through modulation of proinflammatory and profibrogenic mediator galectin-3.

## STUDIES I

Zagayko A. L., Lytk

National University  
d.v.lytkin@gmail.com

**Introduction.** Exemestane is usually used for a cancer which inhibits steroidogenesis (with mineralcorticoids). Exemestane causes decreasing. According to research was that Exemestane causes decreasing. According to research was that Exemestane causes decreasing.

**Material and methods.** 19 animals of 8 weeks (80-100 g) were orally administered Exemestane. Exemestane was control. After Exemestane administration performed with the condition of the animals. The coefficient of the animals measured by standard.

**Results.** 19 animals indicators of ascites Exemestane the level of aldosterone by 10% by contrast.

**Conclusions.** The metabolism of Exemestane requires Exemestane requires effect could expand.